DexComDXCM
DXCM
About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Employees: 10,300
0
Funds holding %
of 7,321 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
21% more repeat investments, than reductions
Existing positions increased: 368 | Existing positions reduced: 303
19% more call options, than puts
Call options by funds: $401M | Put options by funds: $337M
0.11% more ownership
Funds ownership: 91.2% [Q4 2024] → 91.31% (+0.11%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 7 (+0) [Q1 2025]
4% less first-time investments, than exits
New positions opened: 109 | Existing positions closed: 114
2% less funds holding
Funds holding: 932 [Q4 2024] → 911 (-21) [Q1 2025]
12% less capital invested
Capital invested by funds: $27.7B [Q4 2024] → $24.3B (-$3.4B) [Q1 2025]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$89
6%
upside
Avg. target
$99
18%
upside
High target
$106
26%
upside
9 analyst ratings
7 positive
78%
2 neutral
22%
0 negative
0%
Mizuho Anthony Petrone | 19%upside $100 | Outperform Maintained | 16 Jul 2025 |
Morgan Stanley Patrick Wood | 6%upside $89 | Equal-Weight Maintained | 15 Jul 2025 |
Truist Securities Richard Newitter | 22%upside $102 | Buy Initiated | 16 Jun 2025 |
Goldman Sachs Kate McShane | 24%upside $104 | Buy Initiated | 30 May 2025 |
Citigroup Joanne Wuensch | 22%upside $102 | Buy Maintained | 22 May 2025 |
Financial journalist opinion
Based on 13 articles about DXCM published over the past 30 days
Neutral
Business Wire
1 day ago
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This year's Dexcom U roster welcomes 13 new athletes from colleges and universities across the country — including the University of Oregon, San Diego State University, and Northwestern University — representing 12 sports suc.
Positive
Zacks Investment Research
4 days ago
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Neutral
GlobeNewsWire
1 week ago
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
Positive
Kiplinger
1 week ago
The Best Growth Stocks to Buy
Growth stocks can create significant returns for investors, but what are they and how do you find the best ones? We take a closer look here.
Positive
The Motley Fool
1 week ago
2 Stocks to Buy on the Dip and Hold for 10 Years
One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities.
Positive
Zacks Investment Research
2 weeks ago
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
2 weeks ago
3 Reasons Growth Investors Will Love DexCom (DXCM)
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Neutral
Investors Business Daily
2 weeks ago
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech.
Neutral
Business Wire
2 weeks ago
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and wil.
Positive
Zacks Investment Research
3 weeks ago
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Charts implemented using Lightweight Charts™